Recent News

• 09.02.2025 - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.02.2025 - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.29.2025 - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
• 08.29.2025 - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
• 08.14.2025 - Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
• 08.14.2025 - Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
• 08.01.2025 - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.01.2025 - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.15.2025 - ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Recent Filings

• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 144 Report of proposed sale of securities
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.22.2025 - 144 Report of proposed sale of securities
• 07.18.2025 - 8-K Current report